<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01446731</url>
  </required_header>
  <id_info>
    <org_study_id>UR1121</org_study_id>
    <nct_id>NCT01446731</nct_id>
  </id_info>
  <brief_title>Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer</brief_title>
  <official_title>Dendritic Cell Vaccination in Combination With Docetaxel for Patients With Cancer Prostate - a Randomized Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inge Marie Svane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase II trial including 40 patients with castration resistant&#xD;
      metastatic cancer prostate (CRMPC).&#xD;
&#xD;
      Patients will be randomized between treatment with a dendritic cell vaccine plus docetaxel&#xD;
      and docetaxel alone.&#xD;
&#xD;
      The primary objective is to evaluate the vaccine specific immune response and patients will&#xD;
      be evlauated with blood tests and DTH reactions during the treatment course.&#xD;
&#xD;
      Secondary objectives are to evaluate clinical response by objective response&#xD;
      (RECIST-criteria, 18F-NaF-PET/CT scan), PSA response, pain response and finally we determine&#xD;
      time to progression and overall survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment in details:&#xD;
&#xD;
      Dendritic cell (DC) vaccination The DC vaccine consists of adherent monocytes collected by&#xD;
      leukapheresis. Monocytes are stimulated with GM-CSF and IL-4, and IL-1β, TNFα, IL-6 and PGE2&#xD;
      are used for further maturation.&#xD;
&#xD;
      DCs are transfected with PSA, PAP, survivin and hTERT mRNA. DC vaccines will only be given to&#xD;
      patients in ARM A&#xD;
&#xD;
      Docetaxel:&#xD;
&#xD;
      Docetaxel will be given as an i.v. infusion every third week, 75 mg/m2 according to standard&#xD;
      treatment. Patients will be pretreated with prednisolon before infusion with Docetaxel.&#xD;
      Continuous treatment with prednisolon will not be administered.&#xD;
&#xD;
      Treatment schedule:&#xD;
&#xD;
      The DC vaccination will be administered once a week in two out of three weeks for the first&#xD;
      12 weeks. After 12 weeks the DC vaccination will be given once every three weeks as long as&#xD;
      Docetaxel is given. If the disease does not progress but the patient stop treatment with&#xD;
      Docetaxel (because of side effects) the vaccine treatment can continue until disease&#xD;
      progression.&#xD;
&#xD;
      Evaluation in details:&#xD;
&#xD;
      Immunological evaluation:&#xD;
&#xD;
      Blood tests:&#xD;
&#xD;
      100 ml blood will be drawn from the patient together with the first (baseline), the third and&#xD;
      the fourth infusion of Docetaxel, and every third month thereafter.&#xD;
&#xD;
      DTH:&#xD;
&#xD;
      DTH with 3 i.d. injections consisting of media (neg. test), naked DCs and mRNA transfected&#xD;
      DCs will be performed at baseline (together with 1st vaccine), together with the 5th vaccine&#xD;
      and after three months of treatment (8th vaccine). 48 hours after the DTH at 5th vaccine a&#xD;
      biopsy will be taken from the DTH area.&#xD;
&#xD;
      Clinical evaluation:&#xD;
&#xD;
      PSA:&#xD;
&#xD;
      Patients will be evaluated with PSA measurements during the treatment. All patients will&#xD;
      receive at least 4 treatments with Docetaxel even if PSA is rising.&#xD;
&#xD;
      18F-NaF (&quot;bone&quot;) PET/CT scan: All patients will have a bone-PET/CT scan at baseline. For&#xD;
      patients with measurable lesions a PET/CT scan will be performed every three months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological response</measure>
    <time_frame>2 years</time_frame>
    <description>The induction of vaccine specific immune responses will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>2 years</time_frame>
    <description>Clinical response will be assessed using PSA measurements, pain response and PET/CT scans (according to RECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DC vaccine (mRNA transfected dendritic cell) + Docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA transfected dendritic cell</intervention_name>
    <description>Autologues monocytes are matured into dendritic cells which are then transfected with mRNA from PSA, PAP, survivin and hTERT.&#xD;
5x 10e6 DCs are given as intradermal injections in the groin Day 8 and Day 15 in a 3 week period repeated 4 times and thereafter Day 8 in a 3 week period until progression (no maximum duration).</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological verified CRMPC in progression, defined by&#xD;
&#xD;
               1. RECIST-criteria and/or&#xD;
&#xD;
               2. PSA increase to more than baseline in two consecutive measurements&#xD;
&#xD;
          2. Treatment with Docetaxel is indicated&#xD;
&#xD;
          3. Age &gt; 18 years old&#xD;
&#xD;
          4. ECOG performance status ≤2&#xD;
&#xD;
          5. Life expectancy &gt; 3 months&#xD;
&#xD;
          6. Normal organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other malignant tumors&#xD;
&#xD;
          2. Severe heard or lung disorders&#xD;
&#xD;
          3. Infection with HIV, hepatitis, tuberculosis.&#xD;
&#xD;
          4. Severe allergy or previous anaphylactic reactions&#xD;
&#xD;
          5. Active autoimmune disease&#xD;
&#xD;
          6. Treatment with immunosuppressive drugs (including prednisolon, methotrexat)7.&#xD;
             Co-treatment with other experimental treatments, other antineoplastic treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Kongsted, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CCIT / Department of Oncology, Herlev Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Cancer Immune Therapy, Dept. of Haematology/Oncology</name>
      <address>
        <city>Copenhagen</city>
        <state>Herlev</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>October 2, 2011</study_first_submitted>
  <study_first_submitted_qc>October 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2011</study_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Inge Marie Svane</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

